CN105837666A - Protein for diagnosis of diabetic retinopathy - Google Patents

Protein for diagnosis of diabetic retinopathy Download PDF

Info

Publication number
CN105837666A
CN105837666A CN201511003891.7A CN201511003891A CN105837666A CN 105837666 A CN105837666 A CN 105837666A CN 201511003891 A CN201511003891 A CN 201511003891A CN 105837666 A CN105837666 A CN 105837666A
Authority
CN
China
Prior art keywords
protein
diabetic retinopathy
diagnosis
peptide chain
amino acid
Prior art date
Application number
CN201511003891.7A
Other languages
Chinese (zh)
Inventor
田梗
米佳
倪天辉
刘爽
刘芳
王丹
闫冬
李敏
张海利
Original Assignee
田梗
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 田梗 filed Critical 田梗
Priority to CN201511003891.7A priority Critical patent/CN105837666A/en
Publication of CN105837666A publication Critical patent/CN105837666A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy

Abstract

The invention discloses a protein for diagnosis of diabetic retinopathy. A peptide chain of the protein can effectively diagnose amino acids of diabetic retinopathy. A peptide chain amino acid sequence of the protein is an annular sequence and has a certain acidity. The peptide chain of the protein for diagnosis of diabetic retinopathy can effectively diagnose amino acids of diabetic retinopathy and has good diagnosis effects. The peptide chain amino acid sequence of the protein is an annular sequence. In a diagnosis reaction, if the peptide chain is broken, diabetic retinopathy is determined. The protein produces effective diagnosis effects and produces an accurate diagnosis result. The amino acid sequence has acidity and can effectively produce acid-base bonding effects in a reaction of the protein and a diabetic retinopathy pathogen and produce good diagnosis effects.

Description

一种用于诊断糖尿病性视网膜病的蛋白质 A protein diagnostic for diabetic retinopathy

技术领域 FIELD

[0001]本发明涉及一种蛋白质,具体涉及一种用于诊断糖尿病性视网膜病的蛋白质,属于生物医疗技术领域。 [0001] The present invention relates to a protein, particularly relates to a protein for diagnosing diabetic retinopathy, which belongs to the field of biomedical technology.

背景技术 Background technique

[0002]糖尿病性视网膜病变是糖尿病性微血管病变中最重要的表现,是一种具有特异性改变的眼底病变,是糖尿病的严重并发症之一,糖尿病性视网膜病变是主要致盲眼病之一。 [0002] Diabetic retinopathy is diabetic microangiopathy most important manifestation, is a kind of specific changes retinopathy, is one of the serious complications of diabetes, diabetic retinopathy is a major cause of blindness. 无论是否使用胰岛素治疗,都可发生糖尿病性视网膜病变。 Whether or not treated with insulin, diabetic retinopathy can occur. 糖尿病损害视网膜主要是由于血糖增高,小血管管壁增厚,渗透性增大,使小血管更易变形和渗漏。 Diabetic retinal damage mainly due to increased blood sugar, small vessel wall thickening, increased permeability, and small blood vessels more deformable leakage. 糖尿病视网膜病变的严重性和视力下降的程度与血糖水平控制情况以及患糖尿病时间的长短有关,患病时间长短尤为重要,一般患糖尿病至少10年后才出现糖尿病性视网膜病变,所以能够及时的诊断糖尿病性视网膜病非常重要,这样可以及时的为病人治疗,所以现在急需一种蛋白质来用于诊断糖尿病性视网膜病。 Diabetic retinopathy severity and extent of vision loss and control blood sugar levels as well as duration of diabetes is related to the length, duration of illness is particularly important, diabetic retinopathy, diabetes generally occurs at least 10 years after, it is possible to timely diagnosis diabetic retinopathy is very important so that timely treatment for patients, so now an urgent need for a protein to the diagnosis of diabetic retinopathy.

发明内容 SUMMARY

[0003]本发明要解决的技术问题克服现有的缺陷,提供一种用于诊断糖尿病性视网膜病的蛋白质,通过蛋白质中的肽链中有可以有效诊断糖尿病性视网膜病的氨基酸,能够起到良好的诊断效果,而且通过该蛋白质中的肽链氨基酸序列为环形序列,可以在诊断反应时发生如果肽链断裂就可以诊断患有糖尿病性视网膜病,能够有效的起到诊断的作用,可以使诊断更加精准,而且通过氨基酸序列具有一定的酸性,可以在蛋白质与糖尿病性视网膜病病原体反应时,可以有效的起到酸碱结合的效果,能够起到良好的诊断效果,可以有效解决背景技术中的问题。 [0003] The present invention is to overcome the problems of the prior art drawbacks, there is provided a protein for diagnosing diabetic retinopathy by a peptide chain of amino acids in a protein can be effectively diagnosis of diabetic retinopathy, can play good diagnostic results, but also by the amino acid sequence of the protein peptide chain in an annular sequence, the reaction may occur at the time of diagnosis if the peptide strand breaks can be diagnosed with diabetic retinopathy, can effectively play the role of diagnosis can be made more accurate diagnosis, but also by having a certain acidic amino acid sequences, a protein may be associated with diabetic retinopathy pathogens reaction, can effectively play the effect of acid binding, can play a good diagnostic effect, can effectively solve the background art The problem.

[0004]为了解决上述技术问题,本发明提供了如下的技术方案: [0004] To solve the above problems, the present invention provides the following technical solutions:

[0005]本发明提供一种用于诊断糖尿病性视网膜病的蛋白质,所述该蛋白质中的肽链中有可以有效诊断糖尿病性视网膜病的氨基酸,所述该蛋白质中的肽链氨基酸序列为环形序列,所述氨基酸序列具有一定的酸性。 [0005] The present invention provides a protein for diagnosing diabetic retinopathy, the peptide chain of the protein has amino acid can be efficiently diagnosis of diabetic retinopathy, the amino acid sequence of the peptide chain of the protein in the annular sequence, the amino acid sequence of a certain acidity.

[0006]作为本发明的一种优选技术方案,所述该蛋白质为片段中有SEQ ID N0:1描述的妝序列的蛋白质。 [0006] As a preferred aspect of the present invention, the protein is a fragment which has SEQ ID N0: protein sequence described in 1 makeup.

[0007]作为本发明的一种优选技术方案,所述该蛋白质为含有SEQ ID N0:2描述的肽序列蛋白质。 [0007] As a preferred aspect of the present invention, said the protein containing SEQ ID N0: 2, a peptide sequence of the protein described.

[0008]作为本发明的一种优选技术方案,所述该蛋白质为肽链在发生反应时易断裂的蛋白质。 [0008] As a preferred aspect of the present invention, the protein is a peptide chain while reacting breakable protein.

[0009 ]作为本发明的一种优选技术方案,所述该蛋白质内含有糖尿病抗体肽链段。 [0009] As a preferred aspect of the present invention, said protein comprising the peptide segments antibody diabetes.

[0010]本发明所达到的有益效果是:该种用于诊断糖尿病性视网膜病的蛋白质,通过蛋白质为片段中有SEQ ID NO:1和SEQ ID NO:2描述的肽序列,能够更好的诊断糖尿病性视网膜病,而且通过蛋白质为肽链在发生反应时易断裂的蛋白质,便于更好的观察诊断时蛋白质发生的变化,有利于诊断,而且通过蛋白质内含有糖尿病抗体肽链段,能够更好的和病原体发生反应,可以使诊断更加的准确。 [0010] The present invention to achieve the beneficial effects: the proteins for diagnosing diabetic retinopathy by a fragment of the protein has SEQ ID NO: 1 and SEQ ID NO: 2 peptide sequence described herein, can be better diagnosis of diabetic retinopathy, and the protein is a peptide chain by reacting breakable when a protein to facilitate protein changes that occur when a better observation of diagnosis, facilitate diagnosis of diabetes and the antibody by a peptide segment containing the protein can be more good and pathogens react, can make the diagnosis more accurate.

具体实施方式 Detailed ways

[0011]以下结合实施例对本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。 [0011] In the following examples of preferred embodiments of the invention are described, it should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention and are not intended to limit the present invention.

[0012] 实施例1: [0012] Example 1:

[0013]先从20名以上患有糖尿病性视网膜病的病人的体中取出一些带有病原体的蛋白质,然后再从20名以上的正常人体中取出正常的蛋白质,然后将蛋白质放入反应器中,然后再向各个反应器中加入该种诊断蛋白质,然后把反应器放入一个合适的环境中,过段时间将反应器拿出放在显微镜下观察,该诊断蛋白质是否发生肽链断裂。 [0013] than the patient's body 20 to start with diabetic retinopathy remove some protein with a pathogen, and then remove the normal protein from the above normal human body 20, and then the protein in a reactor then again added to each reactor of the kind of diagnostic protein, then the reactor was placed in a suitable environment, over time out of the reactor under a microscope, whether the diagnostic protein peptide chain scission occurs.

[0014]以本实施例的方法,能够很好的检测诊断糖尿病性视网膜病,如果发生断裂就证明是检测带有病原体的蛋白质,从而表示患有糖尿病性视网膜病;如果不是就证明是检测的正常蛋白质,从而表示并没有患病。 [0014] In the method according to the present embodiment, can be a good detection and diagnosis of diabetic retinopathy, if fracture occurs proved to be detected with a pathogen protein, thereby indicating diabetic retinopathy; if not proved to be detected normal protein, which said there was no illness.

[0015] 实施例2: [0015] Example 2:

[0016]先从20名以上患有糖尿病性视网膜病的病人的体中取出一些带有病原体的蛋白质,然后再从20名以上的正常人体中取出正常的蛋白质,然后蛋白质分别放入各个反应器中,然后将该诊断蛋白质分别加入各个反应器中,然后使用显微镜观察它们之间的反应。 [0016] than the patient's body 20 to start with diabetic retinopathy remove some protein with a pathogen, and then taken out from the normal protein of 20 or more normal human, the proteins were then placed in each reactor then the diagnostic proteins were added to each reactor, and then using a microscope to observe the reaction between them.

[0017]以本实施例的方法,能够很好的检测诊断糖尿病性视网膜病,如果在观察的时候两种蛋白质之间的反应出现酸碱结合的现象就证明该反应器中加入的是带有病原体的蛋白质,从而诊断出患有糖尿病性视网膜病,如果两种蛋白质之间的反应出现酸碱结合的现象就证明该反应器中加入的是正常蛋白质,从而诊断出没有患有糖尿病性视网膜病。 [0017] In the method according to the present embodiment, can be a good detection and diagnosis of diabetic retinopathy, if the reaction occurs when the observation acid binding between two proteins proved that the phenomenon of reactor is added with pathogen protein, thereby diagnosed with diabetic retinopathy, if the reaction between the two acid-base binding proteins proved that the phenomenon of reactor is added to normal protein, thereby not diagnosed with diabetic retinopathy .

[0018]最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。 [0018] Finally, it should be noted that: the above embodiments are only preferred embodiments of the present invention, but the present invention is not intended to limit the present invention. Although the detailed description of the embodiments, those skilled in the art that aspect, each of which can still be described embodiments of the foregoing embodiment may be modified, or some technical features equivalents. 凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。 Any modification within the spirit and principle of the present invention, made, equivalent substitutions, improvements, etc., should be included within the scope of the present invention.

Claims (5)

1.一种用于诊断糖尿病性视网膜病的蛋白质,其特征在于,所述该蛋白质中的肽链中有可以有效诊断糖尿病性视网膜病的氨基酸,所述该蛋白质中的肽链氨基酸序列为环形序列,所述氨基酸序列具有一定的酸性。 A protein diagnostic for diabetic retinopathy, wherein the peptide chain of the protein in amino acid has effective diagnosis of diabetic retinopathy, the amino acid sequence of the peptide chain of the protein in the annular sequence, the amino acid sequence of a certain acidity.
2.根据权利要求1所述的一种用于诊断糖尿病性视网膜病的蛋白质,其特征在于,所述该蛋白质为片段中有SEQ ID NO:1描述的肽序列的蛋白质。 2. A method according to claim 1 protein diagnostics for diabetic retinopathy, wherein said protein is a fragment which has SEQ ID NO: 1 peptide sequence of the protein described.
3.根据权利要求1所述的一种用于诊断糖尿病性视网膜病的蛋白质,其特征在于,所述该蛋白质为含有SEQ ID N0:2描述的肽序列蛋白质。 According to one of the claims 1 protein diagnostics for diabetic retinopathy, wherein said protein is comprising the SEQ ID N0: 2, a peptide sequence of the protein described.
4.根据权利要求1所述的一种用于诊断糖尿病性视网膜病的蛋白质,其特征在于,所述该蛋白质为肽链在发生反应时易断裂的蛋白质。 According to one of the claims 1 protein diagnostics for diabetic retinopathy, wherein the said protein is a peptide chain while reacting breakable protein.
5.根据权利要求1所述的一种用于诊断糖尿病性视网膜病的蛋白质,其特征在于,所述该蛋白质内含有糖尿病抗体肽链段。 According to one of the claims 1 protein diagnostics for diabetic retinopathy, wherein the antibody within the protein peptide segments comprising diabetes.
CN201511003891.7A 2015-12-30 2015-12-30 Protein for diagnosis of diabetic retinopathy CN105837666A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511003891.7A CN105837666A (en) 2015-12-30 2015-12-30 Protein for diagnosis of diabetic retinopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511003891.7A CN105837666A (en) 2015-12-30 2015-12-30 Protein for diagnosis of diabetic retinopathy

Publications (1)

Publication Number Publication Date
CN105837666A true CN105837666A (en) 2016-08-10

Family

ID=56580420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511003891.7A CN105837666A (en) 2015-12-30 2015-12-30 Protein for diagnosis of diabetic retinopathy

Country Status (1)

Country Link
CN (1) CN105837666A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675246A (en) * 2002-07-16 2005-09-28 艾金株式会社 Protein for diagnosing diabetic retinopathy
WO2008023378A1 (en) * 2006-08-23 2008-02-28 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
CN104080467A (en) * 2011-05-09 2014-10-01 急速制药公司 Integrin receptor antagonists and their methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675246A (en) * 2002-07-16 2005-09-28 艾金株式会社 Protein for diagnosing diabetic retinopathy
WO2008023378A1 (en) * 2006-08-23 2008-02-28 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
CN104080467A (en) * 2011-05-09 2014-10-01 急速制药公司 Integrin receptor antagonists and their methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
仝小林: "《糖尿病中西医防治的关键问题和临床对策》", 30 September 2007, 中国医药科技出版社 *
宓志均: "《实用糖尿病防治手册》", 31 January 2001, 东方出版中心 *
胡仁明: "糖尿病肾病的诊断和防治—中国糖尿病肾病诊断和治疗的专家共识解读", 《糖尿病天地·临床》 *

Similar Documents

Publication Publication Date Title
Eklund et al. Chronic pain 5 years after randomized comparison of laparoscopic and Lichtenstein inguinal hernia repair
Leida et al. A randomized comparison of primary closure and T-tube drainage of the common bile duct after laparoscopic choledochotomy
Otto et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate
Saeed et al. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection.
Vincent et al. Sepsis definitions: time for change
Chen et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely
Danckert et al. Direct effects of prismatic lenses on visuomotor control: an event‐related functional MRI study
EA201390121A1 (en) Method and system for performing remote monitoring and treatment
Welch Overdiagnosis and mammography screening
Towns et al. Sera from patients with type 2 diabetes and neuropathy induce autophagy and colocalization with mitochondria in SY5Y cells
Kim et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels
Meyer et al. Increased error-related brain activity in six-year-old children with clinical anxiety
Campochiaro et al. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study
Davidson et al. Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats
WO2009100131A3 (en) Process to diagnose or treat brain injury
Maran et al. Double blind clinical and laboratory study of hypoglycaemia with human and porcine insulin in diabetic patients reporting hypoglycaemia unawareness after transferring to human insulin.
Yokobori et al. Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model
McEvoy et al. The sleep apnea cardiovascular endpoints (SAVE) trial: Rationale and start-up phase
Abdullah et al. Late-onset Nipah virus encephalitis 11 years after the initial outbreak: A case report.
Sarkar et al. Leptospirosis: a re-emerging infection
Hubbard III Surgical management of retinopathy of prematurity
WO2012138913A3 (en) In vivo immunomagnetic hyperthermia platform for any cell or virus having a target surface receptor
Tsai Optical coherence tomography measurement of retinal nerve fiber layer after acute primary angle closure with normal visual field
Weissman et al. Pontine myelinolysis and delayed encephalopathy following the rapid correction of acute hyponatremia
Auinger et al. Baseline OCT measurements in the Idiopathic Intracranial Hypertension Treatment Trial, part II: correlations and relationship to clinical features.

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination